Sanofi (NASDAQ:SNY) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 15.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 133,604 shares of the company's stock after acquiring an additional 18,274 shares during the period. Allspring Global Investments Holdings LLC's holdings in Sanofi were worth $7,260,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Invesco Ltd. lifted its position in shares of Sanofi by 3.5% during the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after buying an additional 408,752 shares during the last quarter. Bank of America Corp DE boosted its stake in Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after acquiring an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Boston Partners increased its position in shares of Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Sanofi by 10.8% during the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after purchasing an additional 369,530 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 0.2%

NASDAQ:SNY traded down $0.07 on Monday, hitting $48.23. The stock had a trading volume of 1,330,890 shares, compared to its average volume of 2,334,670. The company has a fifty day moving average price of $50.61 and a two-hundred day moving average price of $52.12. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The stock has a market cap of $118.27 billion, a price-to-earnings ratio of 17.23, a PEG ratio of 1.05 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period last year, the company earned $1.78 EPS. The company's quarterly revenue was down 11.0% on a year-over-year basis. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were paid a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research analyst reports. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Sanofi currently has a consensus rating of "Buy" and an average target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.